Home>
Medical News>
Physician's First Watch

Physician's First Watch:
Medical News from Journal Watch

A free daily alert on current news that affects your practice — from medical journals, government agencies, scientific conferences, and major media reports.

May 16, 2012

FDA Panel Recommends Rapid, At-Home HIV Test

An FDA advisory panel voted unanimously on Tuesday to recommend approval of the first rapid, over-the-counter HIV antibody test.

The panel said the OraQuick In-Home HIV Test is safe and effective. However, some research suggested it had low sensitivity, about 93%. False-negative results could lead people with HIV to take fewer precautions, Reuters points out.

The oral swab test produces results in about 20 minutes and, if approved, is expected to cost less than $60.

LINK(S):

Reuters story (Free)

Associated Press story (Free)

FDA summary of test (Free PDF)

Published in Physician's First Watch May 16, 2012

Drug to Prevent Alzheimer's Will Be Tested in a Large Extended Family at Risk

Patients may ask about news reports on a 5-year clinical trial — that's just starting — of a drug to prevent Alzheimer disease. The drug, Crenezumab, blocks formation of amyloid plaques.

The New York Times says Crenezumab will be tested in some 300 members of an extended Colombian family who carry a specific genetic mutation associated with early-onset Alzheimer's. The drug is a mouse-derived, humanized monoclonal antibody against beta-amyloid.

LINK(S):

New York Times story (Free)

Wikipedia entry on Crenezumab (Free)

Published in Physician's First Watch May 16, 2012

Health, United States, 2011— CDC's Annual Statistics Treat for the Data-Obsessed

The National Center for Health Statistics has released its 35th annual compilation of statistics on health in the U.S. This year's edition features a section on socioeconomic status and health.

If you like numbers (or just winning office bets), we highly recommend this.

LINK(S):

Health, United States, 2011 website (Free)

Published in Physician's First Watch May 16, 2012

May 15, 2012

CT Colon Screening Without Laxatives Reliably Finds Lesions Above 10 mm in Size

Computed tomographic colonography (CTC) without use of laxatives finds significant favor among patients, but lesions smaller than 10 mm may escape detection, according to a multicenter study in the Annals of Internal Medicine.

U.S. investigators examined some 600 patients. First, all underwent CTC with use of a marker (but not laxatives) that allowed feces to be "subtracted" from the image. The same patients underwent optical colonoscopy 5 weeks later, with laxative preparation.

The sensitivity for detecting lesions 10 mm or larger was roughly the same with both methods: 91% for CTC and 95% for colonoscopy. For smaller lesions, however, sensitivity was much less: for lesions 6 mm or larger, for example, CTC scored only 59%, versus 76% with optical colonoscopy.

Patients preferred CTC over colonoscopy by a nearly two-to-one margin.

LINK(S):

Annals of Internal Medicine article (Free abstract)

Published in Physician's First Watch May 15, 2012

Exercise Testing in Asymptomatic Patients After Revascularization: Worth the Effort?

Exercise echocardiography in asymptomatic patients after revascularization can identify those at high risk, but these patients do not necessarily benefit from repeat revascularization, according to a retrospective study in the Archives of Internal Medicine.

Researchers studied some 2100 asymptomatic patients who underwent exercise echocardiography roughly 4 years after percutaneous coronary intervention or coronary artery bypass grafting. Of 13% of patients with ischemia on exercise testing, one third had a subsequent revascularization during nearly 6 years of follow-up. While patients with ischemia had a greater mortality risk, repeat revascularization of these patients did not improve survival.

A commentator points out that "routine periodic stress testing in asymptomatic patients following coronary revascularization is associated with high rates of resource utilization and high costs." He concludes: "Until well-supported data become available supporting such a strategy, routine testing in asymptomatic patients is probably not worth the effort."

LINK(S):

Archives of Internal Medicine article (Free abstract)

Archives of Internal Medicine comment (Free)

Published in Physician's First Watch May 15, 2012

New Label Warnings for Fingolimod

The FDA announced on Monday new warnings about potential cardiovascular effects of the multiple sclerosis drug fingolimod (Gilenya), following a review of clinical trial data prompted by the death of one patient after the first dose of the drug.

The agency noted that the death was not definitively tied to fingolimod, but that the drug causes a biphasic drop in heart rate, at about 6 hours and at 12 to 20 hours after the first dose.

Fingolimod is now contraindicated for patients with certain heart conditions or events within the previous 6 months (including MI, stroke, and transient ischemic attack) and in those who take Class Ia or Class III antiarrhythmic medications.

The FDA also now recommends that cardiovascular monitoring be extended beyond 6 hours after the first dose in certain higher-risk patients.

LINK(S):

FDA MedWatch safety alert (Free)

New fingolimod label (Free PDF)

Published in Physician's First Watch May 15, 2012

After 30 Years, Still Warning About the Direction of U.S. Healthcare

Dr. Arnold Relman, who first warned in a 1980 essay against the rise of the "new medical-industrial complex," offers another warning, this time in BMJ. (Clinical Conversations has an interview with him. Listen via the link below.)

While Relman's 1980 essay called for more study of an emerging situation in which market forces were distorting the U.S. healthcare system, he now describes a system headed inevitably toward bankruptcy and in need of major reform. Physicians, fully aware of what their reimbursements will be, have strong incentives to be "overly generous" in recommending services, he writes, but they remain mostly "unfamiliar with the charges made to insurers [and others] for the services they recommend."

He recommends, among other things, the reorganization of the U.S. system into "private, non-profit, multispecialty group practices, in which physicians are paid largely or entirely by salary." He predicts "fierce resistance" to reform "from all those with vested financial interests in the status quo."